Lumara Bio Oncologics GmbHLumara Bio USA Inc., a division of ITM, builds on more than two decades of radiopharmaceutical expertise and is advancing a focused pipeline of targeted therapies for cancers where treatment options remain limited.
That foundation, built on a proven radiopharmaceutical development track record, deep isotope science and advanced manufacturing is what sets Lumara Bio apart at a critical moment in the evolution of radiopharmaceutical medicine.
Above all, we are driven by a single focus: making a real difference for people living with hard-to-treat cancers.
Dr. Andrew Cavey, CEO of ITM.
A new chapter begins.
Discover Lumara Bio and the story behind its launch.